[{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"5cfe778d-fe5e-47ad-9d92-bcdc82f98727","acronym":"SORENTO","url":"https://clinicaltrials.gov/study/NCT05050942","created_at":"2021-09-21T11:53:31.080Z","updated_at":"2024-07-02T16:35:22.027Z","phase":"Phase 3","brief_title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","source_id_and_acronym":"NCT05050942 - SORENTO","lead_sponsor":"Camurus AB","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • octreotide acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 332","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-26"},{"id":"86e6304f-18fe-45fe-88fc-ade5048e2472","acronym":"AIM-NETs","url":"https://clinicaltrials.gov/study/NCT04696042","created_at":"2021-01-19T20:49:35.455Z","updated_at":"2024-07-02T16:35:42.517Z","phase":"","brief_title":"Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs","source_id_and_acronym":"NCT04696042 - AIM-NETs","lead_sponsor":"Asan Medical Center","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2023-07-19"},{"id":"34bbec34-4daa-4d0a-80bd-efb11de7e324","acronym":"PALACE","url":"https://clinicaltrials.gov/study/NCT04852679","created_at":"2021-04-21T11:53:31.620Z","updated_at":"2024-07-02T16:35:57.483Z","phase":"Phase 3","brief_title":"Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs","source_id_and_acronym":"NCT04852679 - PALACE","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 01/13/2023","study_completion_date":" 01/13/2023","last_update_posted":"2023-01-18"},{"id":"ec1adf57-4b93-40ed-a520-5818d6ccc8e0","acronym":"ELECT","url":"https://clinicaltrials.gov/study/NCT00774930","created_at":"2021-01-18T02:55:41.727Z","updated_at":"2024-07-02T16:36:02.435Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","source_id_and_acronym":"NCT00774930 - ELECT","lead_sponsor":"Ipsen","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2022-10-14"},{"id":"058d1321-7be9-48a4-947c-65800088332e","acronym":"CLARINET","url":"https://clinicaltrials.gov/study/NCT00353496","created_at":"2021-01-18T01:13:26.014Z","updated_at":"2024-07-02T16:36:02.649Z","phase":"Phase 3","brief_title":"Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","source_id_and_acronym":"NCT00353496 - CLARINET","lead_sponsor":"Ipsen","biomarkers":" CHGA","pipe":"","alterations":" ","tags":["CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2022-10-11"},{"id":"d8d92c20-f9b0-4b65-887c-9b325e1515f6","acronym":"LAMPARA","url":"https://clinicaltrials.gov/study/NCT03946527","created_at":"2021-01-18T19:25:49.115Z","updated_at":"2024-07-02T16:36:02.836Z","phase":"Phase 2","brief_title":"LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)","source_id_and_acronym":"NCT03946527 - LAMPARA","lead_sponsor":"Antonio Fojo","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/17/2019","start_date":" 06/17/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-10-07"},{"id":"1c7411aa-3958-4e55-a6f9-57809423a865","acronym":"CLARINET FORTE","url":"https://clinicaltrials.gov/study/NCT02651987","created_at":"2021-01-18T12:54:41.991Z","updated_at":"2024-07-02T16:36:03.082Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg","source_id_and_acronym":"NCT02651987 - CLARINET FORTE","lead_sponsor":"Ipsen","biomarkers":" SSTR • GAST • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • GAST • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/24/2019","study_completion_date":" 10/24/2019","last_update_posted":"2022-10-03"},{"id":"9ee7a7c0-245d-4c14-9519-3dfa25026101","acronym":"MetNET-2","url":"https://clinicaltrials.gov/study/NCT02823691","created_at":"2021-03-16T19:52:25.378Z","updated_at":"2024-07-02T16:36:29.449Z","phase":"Phase 1","brief_title":"The MetNET-2 Trial","source_id_and_acronym":"NCT02823691 - MetNET-2","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" SSTR2","pipe":"","alterations":" ","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • lanreotide prolonged-release subcutaneous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-06-07"},{"id":"92cb7e06-c38e-40eb-ad94-d0480d7e3999","acronym":"ATLANT","url":"https://clinicaltrials.gov/study/NCT02698410","created_at":"2021-01-18T13:10:24.095Z","updated_at":"2024-07-02T16:36:40.479Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.","source_id_and_acronym":"NCT02698410 - ATLANT","lead_sponsor":"Ipsen","biomarkers":" HER-2 • MGMT • SSTR • SSTR2","pipe":" | ","alterations":" MGMT expression","tags":["HER-2 • MGMT • SSTR • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 02/08/2019","primary_completion_date":" 02/08/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2020-10-01"},{"id":"fd497a08-eccf-47d3-825c-09547d7fe8a1","acronym":"CALM-NET","url":"https://clinicaltrials.gov/study/NCT02075606","created_at":"2021-01-18T09:33:55.162Z","updated_at":"2024-07-02T16:36:59.020Z","phase":"Phase 4","brief_title":"Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients","source_id_and_acronym":"NCT02075606 - CALM-NET","lead_sponsor":"Ipsen","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2019-06-07"},{"id":"5e79e518-b7e4-4b68-a2bf-4b86ff88ab2c","acronym":"SONNET","url":"https://clinicaltrials.gov/study/NCT02231762","created_at":"2021-01-18T10:28:13.866Z","updated_at":"2024-07-02T16:36:59.921Z","phase":"Phase 2","brief_title":"Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET","source_id_and_acronym":"NCT02231762 - SONNET","lead_sponsor":"Ipsen","biomarkers":" SSTR","pipe":" | ","alterations":" MGMT expression • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2019-05-06"},{"id":"2a2dc230-140f-4a20-96d8-ecd219e2c801","acronym":"SOPRANo","url":"https://clinicaltrials.gov/study/NCT01840449","created_at":"2021-01-18T08:11:56.882Z","updated_at":"2024-07-02T16:37:03.875Z","phase":"","brief_title":"Somatuline Predictive Factors in Acromegaly and NET","source_id_and_acronym":"NCT01840449 - SOPRANo","lead_sponsor":"Ipsen","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lanreotide prolonged-release subcutaneous"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2019-01-14"}]